We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Maravai LifeSciences Holdings Inc | NASDAQ:MRVI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 1.19% | 8.52 | 8.51 | 8.53 | 8.61 | 8.42 | 8.58 | 30,577 | 14:37:49 |
1. Name and Address of Reporting Person * GTCR INVESTMENT XI LLC | 2. Issuer Name and Ticker or Trading Symbol MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Class A Common Stock | 9/9/2021 | D(1) | 2931441 (1) | D | $50.00 | 21681033 (2)(3) | I | See footnotes (2)(3) | ||
Class B Common Stock | 9/9/2021 | J(4) | 17068559 (4) | D | (4) | 126239611 (5) | I | See footnote (5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Common Units | (6) | 9/9/2021 | D (1) | 17068559 | (6) | (6) | Class A Common Stock | 17068559 | $50.00 | 126239611 | I | See footnote (7) |
Remarks: Each of the reporting persons is a director-by-deputization solely for purposes of Section 16 of the Securities Exchange Act of 1934. |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
GTCR INVESTMENT XI LLC C/O GTCR, LLC 300 N. LASALLE SUITE 5600 CHICAGO, IL 60654 | X | X | |||
MARAVAI LIFE SCIENCES HOLDINGS, LLC C/O MARAVAI LIFE SCIENCES HOLDINGS, INC. 10770 WATERIDGE CIRCLE SUITE 200 SAN DIEGO, CA 92121 | X | X | |||
MARAVAI LIFE SCIENCES HOLDINGS 2, LLC C/O MARAVAI LIFE SCIENCES HOLDINGS, INC. 10770 WATERIDGE CIRCLE SUITE 200 SAN DIEGO, CA 92121 | X | X | |||
GTCR FUND XI/B LP C/O GTCR LLC 300 N. LASALLE SUITE 5600 CHICAGO, IL 60654 | X | X | |||
GTCR FUND XI/C LP C/O GTCR LLC 300 N. LASALLE SUITE 5600 CHICAGO, IL 60654 | X | X | |||
GTCR CO-INVEST XI LP C/O GTCR LLC 300 N. LASALLE SUITE 5600 CHICAGO, IL 60654 | X | X | |||
GTCR PARTNERS XI/A&C LP C/O GTCR LLC 300 N. LASALLE SUITE 5600 CHICAGO, IL 60654 | X | X | |||
GTCR PARTNERS XI/B LP C/O GTCR LLC 300 N. LASALLE SUITE 5600 CHICAGO, IL 60654 | X | X |
Signatures | ||
/s/ Carl Hull, as chief executive officer of Maravai Life Sciences Holdings, LLC | 9/13/2021 | |
**Signature of Reporting Person | Date | |
/s/ Carl Hull, as chief executive officer of Maravai Life Sciences Holdings 2, LLC | 9/13/2021 | |
**Signature of Reporting Person | Date | |
/s/ Jeffrey Wright, by power of attorney for GTCR Fund XI/B LP | 9/13/2021 | |
**Signature of Reporting Person | Date | |
/s/ Jeffrey Wright, by power of attorney for GTCR Fund XI/C LP | 9/13/2021 | |
**Signature of Reporting Person | Date | |
/s/ Jeffrey Wright, by power of attorney for GTCR Co-Invest XI LP | 9/13/2021 | |
**Signature of Reporting Person | Date | |
/s/ Jeffrey Wright, by power of attorney for GTCR Partners XI/A&C LP | 9/13/2021 | |
**Signature of Reporting Person | Date | |
/s/ Jeffrey Wright, by power of attorney for GTCR Partners XI/B LP | 9/13/2021 | |
**Signature of Reporting Person | Date | |
/s/ Jeffrey Wright, by power of attorney for GTCR Investment XI LLC | 9/13/2021 | |
**Signature of Reporting Person | Date |
1 Year Maravai LifeSciences Chart |
1 Month Maravai LifeSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions